Skip Ribbon Commands
Skip to main content
Translate
Translate
menu iconMenu
search iconSearch

Fluorescent Probes Light Up Cancerous Tumors

 

February 16, 2010  |  

Use of biological probes improve detection and survival in mice

Building on his Nobel Prize-winning work creating fluorescent proteins that light up the inner workings of cells, a team of researchers led by Howard Hughes Medical Institute investigator Roger Tsien, PhD, professor of pharmacology, chemistry and biochemistry at the University of California, San Diego and the

Roger Tsien

Roger Tsien, PhD

Moores UCSD Cancer Center has developed biological probes that can stick to and light up tumors in mice. The scientists were able to spot and remove more cancerous tissue in mice injected with the fluorescent probes than in those mice without the fluorescent probes, upping survival five-fold. The findings – reported online the week of February 15 in the early edition of the Proceedings of the National Academy of Sciences – are the latest steps in research aimed at helping surgeons see the outlines of cancerous tumors in real time, and promise to open new doors to using molecular tools in the operating room.

“The development of biological probes that can guide surgeons, rather than depending only on feel and normal ‘white light’ to see, can provide tools to navigate the body on a molecular level,” said first author Quyen Nguyen, MD, PhD, assistant professor of surgery at the University of California, San Diego School of Medicine.  

Surgeons often rely on feel, look and experience to tell if they have removed all of a tumor while sparing healthy tissue. While the patient lies on the operating table under anesthesia, tissue samples are quickly examined by pathologists, and remaining tumor tissue is sometimes missed, meaning further surgery or a greater likelihood of tumor recurrence. Tsien, Nguyen and colleagues used synthetic molecules called activatable cell penetrating peptides (ACPPs) and microscopic nanoparticles to develop probes carrying fluorescent and magnetic tags. These tags make tumors visible to MRI and allow the tumors to “glow” on the operating table. The team wanted to see if the probes could aid surgeons in seeing more of the tumor, particularly the margins.

In a series of studies, working mainly in mice with implanted human tumors, the researchers showed that if tumors had spread to surrounding tissue, the ACCP-nanoparticle probes enabled them to visualize areas of tumors that they wouldn’t ordinarily see – either because the tissue was buried beneath other tissue or the tumor simply was difficult to distinguish from normal tissue.

Using a technique called PCR (polymerase chain reaction) to measure tumor DNA, they found that, on average, 90 percent fewer cancer cells remained after surgery to remove tumors in mice using the probe-based molecular guidance compared to surgery without it – a 10-fold reduction. They also found that the fluorescently labeled probes hit their mark 93 percent of the time, allowing the researchers to “see” left over tumor tissue. 

According to the scientists, only a single injection of the nanoparticle-based probe containing the fluorescent and magnetic tags was needed in order to use MRI to examine the entire mouse model for tumors before and after surgery, in addition to the real-time guidance in surgery.

Nguyen said that in the future, additional tags may be added, and eventually, a cocktail of personalized probes may be designed for individual types of cancers. If the nanoparticle-based probes are successful in finding tumor cells in humans, the researchers envision using them eventually to deliver chemotherapy drugs to finish off the remaining cancer.

Tsien and Nguyen see many advantages to molecularly guided cancer surgery. Probes can be useful in staging cancer, particularly in prostate cancer, and can be used in a variety of tumor types. In addition, such biological probes can be used in laparoscopic and robotic surgery, where surgeons cannot feel the tumor, and rely much more on sight. If surgeons can completely remove a cancer, it may mean a patient could be cured quickly, and at relatively low cost when compared to long-term chemotherapy.

Additional co-authors include: Emilia Olson, Todd Aguilera, Tao Jiang, Miriam Scadeng, and Lesley Ellies, of UC San Diego.

Funding support came from the Department of Defense Breast Cancer Research Program, the Howard Hughes Medical Institute and the National Institutes of Health.

The Moores UCSD Cancer Center is one of the nation’s 40 National Cancer Institute-designated Comprehensive Cancer Centers, combining research, clinical care and community outreach to advance the prevention, treatment and cure of cancer. For more information, visit UCSD Moores Cancer Center.

# # #

Media Contacts:
Steve Benowitz, 619-543-6163, sbenowitz@ucsd.edu
Jackie Carr, 619-543-6163, jcarr@ucsd.edu


Related Specialties



Media Contact

Related News

4/22/2015
UC San Diego Health System and Scripps Health are partnering to provide improved continuity of patient care, fellowship training and research in hospice and palliative medicine. Under a new five-year ...
4/20/2015
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have discovered a molecular mechanism that connects breast tissue stiffness to tumor metastasis and p ...
4/20/2015
A decrease in the amount of time spent eating and an increase in overnight fasting reduces glucose levels and may reduce the risk of breast cancer among women, report University of California, San Die ...
4/20/2015
The threat of falsified medications, also referred to as counterfeit, fraudulent, and substandard, can be quite real, yet the full scope and prevalence of the problem is poorly understood, say researc ...
4/17/2015
Researchers at the University of California, San Diego School of Medicine have created an in vitro, live-cell artificial vessel that can be used to study both the application and effects of devices us ...
4/16/2015
The increase in use of e-cigarettes has led to heated debates between opponents who question the safety of these devices and proponents who claim the battery-operated products are a useful cessation t ...
4/16/2015
An international team of scientists, led by researchers at University of California, San Diego School of Medicine, have found genetic overlap between Alzheimer’s disease (AD) and two significant cardi ...
4/13/2015
About one quarter of all atrial fibrillation patients at the lowest risk for stroke receive unnecessary blood thinners from cardiology specialists, according to a new study by researchers at Universit ...


Share This Article



Follow Us: